Cimetidine tablets are indicated in:Short-term treatment of active duodenal ulcer.
Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION - Duodenal Ulcer).
Concomitant antacids should be given as needed for relief of pain.
However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine.Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer.
Patients have been maintained on continued treatment with cimetidine 400 mg h.s.
for periods of up to five years.Short-term treatment of active benign gastric ulcer.
There is no information concerning usefulness of treatment periods of longer than 8 weeks.Erosive gastroesophageal reflux disease (GERD).
Erosive esophagitis diagnosed by endoscopy.
Treatment is indicated for 12 weeks for healing of lesions and control of symptoms.
The use of cimetidine beyond 12 weeks has not been established (see DOSAGE AND ADMINISTRATION-GERD).The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas).
-- A PEPTIC ULCER located in the DUODENUM.
-- An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
-- A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.
-- An indication that a person has a condition or disease. Some examples of symptoms are headache, fever, fatigue, nausea, vomiting, and pain.
Gastroesophageal reflux disease
-- Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER. Gastric regurgitation is an extension of this process with retrograde flow into the PHARYNX or MOUTH.
-- A syndrome that is characterized by the triad of severe PEPTIC ULCER, hypersecretion of GASTRIC ACID, and GASTRIN-producing tumors of the PANCREAS or other tissue (GASTRINOMA). This syndrome may be sporadic or be associated with MULTIPLE ENDOCRINE NEOPLASIA TYPE 1.
-- A group of disorders caused by the abnormal proliferation of MAST CELLS in a variety of extracutaneous tissues including bone marrow, liver, spleen, lymph nodes, and gastrointestinal tract. Systemic mastocytosis is commonly seen in adults. These diseases are categorized on the basis of clinical features, pathologic findings, and prognosis.
Multiple Endocrine Neoplasia
-- group of specific, familial syndromes characterized by simultaneous neoplastic transformation of multiple endocrine tissues, typically the parathyroid glands, pancreatic islets, and anterior pituitary.